Title: Remission in rheumatic diseases
Audio summaries of each article may be downloaded directly in MP3 format, or downloaded from AppleiTunes music store.
CME Credit available through Vanderbilt University.
The Journal thanks Abbott, Amgen Inc., Bristol-Myers Squibb, Centocor Inc., Hoffman LaRoche, Novartis Pharmaceuticals Corporation, UCB, Wyeth Pharmaceuticals for support of this Supplement.
pictures and PubMed Link of our Authors.
Webmaster for the Supplement: Andrea Stancati, M.D. Italy
Subscribe to our PodCast for free on iTunes Music Store (need Apple iTunes installed) or download the audio files in .mp3 format.
|Page||Article - [Author(s)]||Abs.||CME||Audio||Media|
|Complexities in defining remission in rheumatic diseases|
T. Pincus, A. Kavanaugh, D. Aletaha, J. Smolen › Free to View
|Remission in rheumatoid arthritis|
|What should be our treatment goal in rheumatoid arthritis today?|
J.S. Smolen, D. Aletaha › Free to View
|ACR remission criteria and response criteria|
V. K. Ranganath, D. Khanna, H. E. Paulus › Free to View
|Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission|
H. Mäkinen, P. Hannonen, T. Sokka › Free to View
|DAS remission cut points|
J. Fransen, P.L.C.M. van Riel › Free to View
|Can remission be maintained with or without further drug therapy in rheumatoid arthritis?|
B. Saleem, S. Nizam, P. Emery › Free to View
|Remission and radiographic progression in rheumatoid arthritis|
A.E. Voskuyl, B.A.C. Dijkmans › Free to View
|Is remission in rheumatoid arthritis associated with radiographic healing?|
R. Rau › Free to View
|Alternatives to strict remission in RA|
|Remission of rheumatoid arthritis: should we care about definitions?|
D. Aletaha, J.S. Smolen › Free to View
|Low disease activity state in rheumatoid arthritis: concepts and derivation of minimal disease activity|
G. Wells, M. Boers, P. Tugwell › Free to View
|A proposed approach to recognise “near-remission” quantitatively without formal joint counts or laboratory tests: a patient self-report questionnaire routine assessment of patient index data (RAPID) score as a guide to a “continuous quality improvement” s|
T. Pincus, Y. Yazici, M. Bergman, C. Swearingen, T. Harrington › Free to View
|Clinical trials and other studies in which low disease activity or remission has been used as an endpoint|
|Remission as the treatment goal – the FIN-RACo trial|
T. Sokka, H. Mäkinen, K. Puolakka, T. Möttönen, P. Hannonen › Free to View
|Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study|
C.F. Allaart, Y.P.M. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, F.C. Breedveld, B.A.C. Dijkmans, FARR study group › Free to View
|Remission in rheumatic diseases other than RA|
|Defining remission in psoriatic arthritis|
A. Kavanaugh, J. Fransen › Free to View
|Remission in ankylosing spondylitis|
J. Zochling, J. Braun › Free to View
|Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis|
C. Mukhtyar, B. Hellmich, D. Jayne, O. Flossmann, R. Luqmani › Free to View
|Assessing remission in systemic lupus erythematosus|
M. Mosca, S. Bombardieri › Free to View
|Remission in juvenile idiopathic arthritis|
A. Ravelli, A. Martini › Free to View
|A journal-based CME Activity|
|Clinical and Experimental Rheumatology: Remission in Rheumatic Diseases|
› Free to View
This journal-based Continuing Medical Education (CME) activity has bee jointly sponsored by Vanderbilt University School of Medicine and Abbott Immunology, Amgen Inc., .Bristol-Myers Squibb, Centocor Inc., Genentech, Novartis Pharmaceuticals Corporation, Pfizer Inc., Wyeth Pharmaceuticals.
This issue is valid for obtaining a maximum of 20 category 1 credits toward the AMA Physician's Recognition Award. Each article has been certified for 0.5 category 1 credit. Each physician should claim only those credits that he/she actually spent in the activity.
To receive the CME credit, for US physicians, please go to page S208-S221